



Bristol-Myers Squibb

Cowen Health Care Conference

Michael Giordano, M.D.
Head of Oncology Development

March 3, 2015

Forward-Looking Information

This presentation contains statements about the Company's future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company's most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations.

In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.

This presentation also contains certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company's website at www.bms.com.




Immuno-Oncology: A Transformational Opportunity for Cancer Patients

BMS I-O Development Approach

Bringing the potential for long-term survival to a broad range of patients

- Broad development in lung, renal, melanoma across multiple lines of treatment
- Accelerated development strategy into additional tumor types
- Differentially invest in I-O combinations
- Rapid development of early clinical assets
- Science driven biomarker approach
- Commitment to strategic business development and external collaboration

Immuno-oncology – Development Portfolio



* Development Partnership

OPDIVO: Ono Pharmaceuticals; Elotuzumab: AbbVie; Lirilumab: Innate Pharma

Partner run study

Extending Leadership Through Partnerships



- Filed in squamous NSCLC (-063)
- Approved in advanced melanoma
- Two Phase 3 trials stopped early due to survival benefit
- Promising data presented in hematological malignancies
– initiated registrational trials
- Expansion of portfolio through Business Development

Lung Cancer

Broad development strategy

- Across histologies, stages of disease, and mutational status
- Both PDL-1 positive and negative
- Committed to evaluating combination regimens

Demonstrated clinical benefit

- Positive data from -063; -017 stopped early due to survival benefit
- Planning for approvals and launches in the US and EU later this year

Melanoma

- Yervoy: first I-O agent to offer the possibility of long term survival
- Opdivo: approved in the US; an important treatment option for melanoma patients
 - -037: more patients have opportunity for durable response
 - -066: first to show overall survival in a Phase 3 study
- Yervoy and Opdivo combination has the potential to further transform the treatment of melanoma

Renal Cell Carcinoma

Our goal is to improve overall survival across the continuum of this disease

- Significant unmet need
- Registrational studies ongoing
 - Second line (monotherapy)
 - First line (combination with Yervoy)
- Registrational study planned for adjuvant setting

Hematological Malignancies

- Build on success of Sprycel and expertise in Immuno-Oncology
- Elotuzumab studies ongoing in 1st and 2nd line multiple myeloma
- Opdivo data presented at ASH 2014
 - Potentially registrational studies ongoing in Hodgkin and non-Hodgkin's Lymphoma

IO Key Data Flow & Events: 2015



- Phase 2 combination with Yervoy (-069) in melanoma at AACR
- Presentation of full data set from -017
- Planned interim analysis from -057
- Presentation of data from new tumor types
- Potential EU approval
- Initiation of combination with Yervoy in lung
- Initiation of additional trials and in additional indications



- Potential data in-house from additional tumor types

Elotuzumab

- Phase 3 data – relapsed/refractory multiple myeloma



Bristol-Myers Squibb

Cowen Health Care Conference

Michael Giordano, M.D.
Head of Oncology Development

March 3, 2015